Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/08/2003US20030087817 Regulation of endogenous gene expression in cells using zinc finger proteins
05/08/2003US20030087816 Anticancer, antitumor agents; genetic engineering
05/08/2003US20030087814 Synergistic mixture of enzyme inhibitor of aldehyde dehydrogenase and monoamine oxidase
05/08/2003US20030087805 Nitrosation-inducible inhibitors biological macromolecules
05/08/2003US20030087803 Insertion drugs into cells, tissue; therapy for brain disorders, central nervous system disorders
05/08/2003US20030087800 Lyme disease; enclosure aperture which applies fipronil to parasites on rodents
05/08/2003US20030087799 Modulation
05/08/2003US20030087789 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
05/08/2003US20030087434 Process for selective expression of nucleic acid products
05/08/2003US20030087430 Treating human for microorganismal infections; administer to human bactericide, monitor microorganismal propagation, evaluate human for infection
05/08/2003US20030087412 Nucleotide sequences coding polypeptide for use in the prevention and treatment of tumors, nervous system, cardiomyopathy, viral and metabolic diseases
05/08/2003US20030087408 Protein for use in the treatment of tumors
05/08/2003US20030087308 Detection of preferential particles in fluids; obtain milling fluid, reduce size of particle sample, screen sample in high throughput assay, monitor activity of particles in sample
05/08/2003US20030087307 Compound for use in the prevention and treatment of respiratory and nervous system disorders
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087303 In vitro screening for ligands of the estrogen receptor
05/08/2003US20030087302 Detection of modulators of advanced glycation end product activity; obtain sample containing advanced glycation end product activity, incubate with peptide monitor adjustment in activity, adjustment in activity indicates modulator
05/08/2003US20030087295 Methods and compositions for the treatment and diagnosis of pain disorders using 9805
05/08/2003US20030087273 Detection of viral enzyme inhibitors; obtain sample containing enzymes, incubate with inhibitor, monitor adjustment in enzyme activy, adjustment in activity indicates inhibitor
05/08/2003US20030087266 IGs as modifiers of the p53 pathway and methods of use
05/08/2003US20030087230 L-Ribo-LNA analogues
05/08/2003US20030086987 Administering formulation containing salvianolic acid B for therapy of inflammatory injury to the cardiovascular system caused by oxidized low density lipoprotein
05/08/2003US20030086986 Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
05/08/2003US20030086984 Treating collected plant material with a solvent to extract a fraction having appetite suppressant activity, separating extraction solution from plant material, removing the solvent from extraction solution and recovering
05/08/2003US20030086981 Glycerin fatty acid ester for palliate a symptom of premenstrual syndrome, a palliative of premenstrual syndrome, oil or fat composition for palliate a symptom of premenstrual syndrome, and food and drink for palliate a symptom of premenstrual syndrome
05/08/2003US20030086980 Method for the suppression of visceral pain by regulating T type calcium channel
05/08/2003US20030086976 Pharmaceutical compositions for poorly soluble drugs
05/08/2003US20030086972 Time-release agents; drug delivery; therapy
05/08/2003US20030086971 For therapy of allergic and/or inflammatory conditions of the skin and airway passages
05/08/2003US20030086970 Delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaqlandin and one or more excipients; for therapy of osteoarthritis or rheumatoid arthritis
05/08/2003US20030086969 Ciprofoxacin-metronidazole antibiotic composition
05/08/2003US20030086968 Administering to human an amount of (-) pantoprazole, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer to alleviate or palliate ulcers
05/08/2003US20030086967 Medicine stability; solubility in an oral cavity, and does not have uncomfortable tastes
05/08/2003US20030086966 Antihistamine formulations for soft gelatin dosage forms
05/08/2003US20030086965 Combination chemotherapy
05/08/2003US20030086964 Methods and compositions for polyene antibiotics with reduced toxicity
05/08/2003US20030086958 Drug delivery
05/08/2003US20030086948 For decreasing the effect of intestinal metabolism on a drug
05/08/2003US20030086933 Therapeutic systems
05/08/2003US20030086916 Administering to the animal a therapeutically effective amount of an agent which is selected from the group consisting of premature vascular senescence ameliorating ebselen-class compounds for therapy of premature vascular senescence
05/08/2003US20030086909 Composition and method for improving function of embryonic kidney transplants
05/08/2003US20030086901 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
05/08/2003US20030086900 Method of treatment using ligand-immunogen conjugates
05/08/2003US20030086899 Chondroitin sulfate containing viscoelastics for use in treating joints
05/08/2003US20030086898 Method for treating hypercholesterolemia with polyallylamine polymers
05/08/2003US20030086881 Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails
05/08/2003US20030086880 Antimicrobial artificial nail composition and methods for preparing and using same
05/08/2003US20030086876 Pharmaceutical formulation of fluticasone propionate
05/08/2003US20030086869 Obtaining sample of blood from mammal; administering digestible first fatty acid- containing substrate; obtaining sample; assaying; determining from the rate of fatty acid absorption of fatty acid-substrate; comparing
05/08/2003US20030086820 Pretreating surfaces that carry prion infected material with a cleaner that attacks prions; treating the surfaces with an oxidizing agent in gaseous form
05/08/2003CA2789114A1 Medical compositions for intravesical treatment of bladder cancer
05/08/2003CA2478059A1 Crystal structure of phosphodiesterase 5 and use thereof
05/08/2003CA2473024A1 Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
05/08/2003CA2468761A1 Novel anticancer compounds
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2466424A1 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
05/08/2003CA2466148A1 Medical compositions for intravesical treatment of bladder cancer
05/08/2003CA2466032A1 Methods and dosage forms for improving the bioavailability of therapeutic agents
05/08/2003CA2465682A1 Methods of treating leukemia
05/08/2003CA2465632A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003CA2465497A1 Bridged bicyclic amino acid-derived (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003CA2465438A1 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells
05/08/2003CA2465429A1 Compounds and method for the treatment of overactive bladder
05/08/2003CA2465405A1 Controlled release compositions for macrolide antimicrobial agents
05/08/2003CA2465399A1 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
05/08/2003CA2465382A1 Indole compound and medicinal use thereof
05/08/2003CA2465369A1 Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
05/08/2003CA2465350A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003CA2465344A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003CA2465316A1 Hydroxy substituted amides for the treatment of alzheimer's disease
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465306A1 Substituted 1h-quinolin-2-one compounds
05/08/2003CA2465305A1 Antiretroviral pyridine and quinoline derivatives
05/08/2003CA2465236A1 Substituted indoles, method for production and use thereof for the inhibition of pain
05/08/2003CA2465140A1 Method for the treatment of overactive bladder
05/08/2003CA2465129A1 Acyclic linker-containing oligonucleotides and uses thereof
05/08/2003CA2465083A1 Non-lauric, non-trans, non-temper fat compositions
05/08/2003CA2465061A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003CA2465040A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003CA2464997A1 Silicon compounds
05/08/2003CA2464995A1 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003CA2464945A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464934A1 Pyrimido [4,5-b] indole derivatives
05/08/2003CA2464924A1 Heteroaromatic carboxamide derivatives for the treatment of inflammation
05/08/2003CA2464889A1 Cytokine-inducing material and cytokine-inducing instrument
05/08/2003CA2464888A1 Pyridine derivatives as nmda-receptor subtype blockers
05/08/2003CA2464727A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003CA2464656A1 Spray drying methods and compositions thereof
05/08/2003CA2464479A1 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003CA2464475A1 Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
05/08/2003CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003CA2464346A1 Water-soluble polymer conjugates of retinoic acid
05/08/2003CA2464342A1 Therapeutic isoquinoline compounds
05/08/2003CA2464303A1 Method for treating retroviral infections
05/08/2003CA2464194A1 N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
05/08/2003CA2464191A1 Substituted benzo[b]azepin-2-one compounds
05/08/2003CA2464031A1 Purine analogs having hsp90-inhibiting activity
05/08/2003CA2463823A1 Aminobenzamide derivatives as glycogen synthase kinase 3.beta. inhibitors
05/08/2003CA2463822A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
1 ... 5476 5477 5478 5479 5480 5481 5482 5483 5484 5485 5486 5487 5488 5489 5490 5491 5492 5493 5494 5495 5496 ... 7860